These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28443701)

  • 1. Evaluation of Dietary Intake, Leisure-Time Physical Activity, and Metabolic Profile in Women with Mutation in the LMNA Gene.
    Monteiro L; Foss-Freitas MC; Navarro A; Pereira F; Coeli F; Carneseca E; Júnior RM; Foss M
    J Am Coll Nutr; 2017; 36(4):248-252. PubMed ID: 28443701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional Body Fat Changes and Metabolic Complications in Children With Dunnigan Lipodystrophy-Causing LMNA Variants.
    Patni N; Li X; Adams-Huet B; Vasandani C; Gomez-Diaz RA; Garg A
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1099-1108. PubMed ID: 30418556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of familial partial lipodystrophy caused by a novel lamin A/C (LMNA) mutation in exon 1 (D47N).
    Kutbay NO; Yurekli BS; Onay H; Altay CT; Atik T; Hekimsoy Z; Saygili F; Akinci B
    Eur J Intern Med; 2016 Apr; 29():37-9. PubMed ID: 26775134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety.
    Vasandani C; Li X; Sekizkardes H; Adams-Huet B; Brown RJ; Garg A
    J Clin Endocrinol Metab; 2020 Jul; 105(7):2132-41. PubMed ID: 32193531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2.
    Resende ATP; Martins CS; Bueno AC; Moreira AC; Foss-Freitas MC; de Castro M
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):94-103. PubMed ID: 30954027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.
    Bidault G; Garcia M; Vantyghem MC; Ducluzeau PH; Morichon R; Thiyagarajah K; Moritz S; Capeau J; Vigouroux C; Béréziat V
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2162-71. PubMed ID: 23846499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FPLD2 LMNA mutation R482W dysregulates iPSC-derived adipocyte function and lipid metabolism.
    Friesen M; Cowan CA
    Biochem Biophys Res Commun; 2018 Jan; 495(1):254-260. PubMed ID: 29108996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irisin levels in LMNA-associated partial lipodystrophies.
    Bensmaïne F; Benomar K; Espiard S; Vahe C; Le Mapihan K; Lion G; Lemdani M; Chazard E; Ernst O; Vigouroux C; Pigny P; Vantyghem MC
    Diabetes Metab; 2019 Jan; 45(1):67-75. PubMed ID: 30165155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Describing the natural history of clinical, biochemical and radiological outcomes of children with familial partial lipodystrophy type 2 (FPLD2) from the United Kingdom: A retrospective case series.
    Zhong ZX; Harris J; Wilber E; Gorman S; Savage DB; O'Rahilly S; Stears A; Williams RM
    Clin Endocrinol (Oxf); 2022 Dec; 97(6):755-762. PubMed ID: 35920656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The p.R482W substitution in A-type lamins deregulates SREBP1 activity in Dunnigan-type familial partial lipodystrophy.
    Vadrot N; Duband-Goulet I; Cabet E; Attanda W; Barateau A; Vicart P; Gerbal F; Briand N; Vigouroux C; Oldenburg AR; Lund EG; Collas P; Buendia B
    Hum Mol Genet; 2015 Apr; 24(7):2096-109. PubMed ID: 25524705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation.
    Wojtanik KM; Edgemon K; Viswanadha S; Lindsey B; Haluzik M; Chen W; Poy G; Reitman M; Londos C
    J Lipid Res; 2009 Jun; 50(6):1068-79. PubMed ID: 19201734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia].
    Sorkina EL; Kalashnikova MF; Melnichenko GA; Tyulpakov AN
    Ter Arkh; 2015; 87(3):83-87. PubMed ID: 26027246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput Second-generation Sequencing Technology Assisted Diagnosis of Familial Partial Lipodystrophy (Type 2 Kobberling-Dunnigan Syndrome): A Case Report.
    Deng M; Chen W; Qi Y
    Comb Chem High Throughput Screen; 2024; 27(2):346-351. PubMed ID: 37231758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lipodystrophic hotspot lamin A p.R482W mutation deregulates the mesodermal inducer T/Brachyury and early vascular differentiation gene networks.
    Briand N; Guénantin AC; Jeziorowska D; Shah A; Mantecon M; Capel E; Garcia M; Oldenburg A; Paulsen J; Hulot JS; Vigouroux C; Collas P
    Hum Mol Genet; 2018 Apr; 27(8):1447-1459. PubMed ID: 29438482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial partial lipodystrophy presenting as metabolic syndrome.
    Chan D; McIntyre AD; Hegele RA; Don-Wauchope AC
    J Clin Lipidol; 2016; 10(6):1488-1491. PubMed ID: 27919367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects.
    Gambineri A; Zanotti L
    Nucleus; 2018; 9(1):392-397. PubMed ID: 30131000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy.
    Araújo-Vilar D; Lattanzi G; González-Méndez B; Costa-Freitas AT; Prieto D; Columbaro M; Mattioli E; Victoria B; Martínez-Sánchez N; Ramazanova A; Fraga M; Beiras A; Forteza J; Domínguez-Gerpe L; Calvo C; Lado-Abeal J
    J Med Genet; 2009 Jan; 46(1):40-8. PubMed ID: 18805829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of an integration-free induced pluripotent stem cell line (PUMCHi001-A) from a patient with familial partial lipodystrophy type 2 (FPLD2) carrying a heterozygous p.R349W (c.1045C > T) mutation in the LMNA gene.
    Xiao C; Yu M; Liu J; Wu H; Deng M; Zhang Q; Xiao X
    Stem Cell Res; 2020 Jan; 42():101651. PubMed ID: 31794942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series.
    Luedtke A; Boschmann M; Colpe C; Engeli S; Adams F; Birkenfeld AL; Haufe S; Rahn G; Luft FC; Schmidt HH; Jordan J
    Horm Metab Res; 2012 Apr; 44(4):306-11. PubMed ID: 22274718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy.
    Akinci B; Onay H; Demir T; Savas-Erdeve Ş; Gen R; Simsir IY; Keskin FE; Erturk MS; Uzum AK; Yaylali GF; Ozdemir NK; Atik T; Ozen S; Yurekli BS; Apaydin T; Altay C; Akinci G; Demir L; Comlekci A; Secil M; Oral EA
    Metabolism; 2017 Jul; 72():109-119. PubMed ID: 28641778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.